Please assess the completion status of the following clinical trial:

Trial Title: Preoperative Intravesical Electromotive Mitomycin-c for Primary Non-muscle Invasive Bladder Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* All patients with primary histologically proven stage pTa-pT1 transitional-cell carcinoma of the bladder~Exclusion Criteria:~* Previous treatments with bacillus Calmette-Guerin, mitomycin-C, or with any other intravesical cytostatic agent~* Concomitant urothelial tumours of the upper urinary tract~* Previous or concomitant muscle-invasive (ie, stage T2 or higher) transitional-cell carcinoma of the bladder~* Bladder capacity less than 200 ml~* Untreated urinary-tract infection~* Disease of upper urinary tract~* Previous radiotherapy to the pelvis~* Other concurrent chemotherapy~* Treatment with radiotherapy-response or biological-response modifiers~* Other malignant diseases within 5 years of trial registration (except for basal-cell carcinoma)~* Pregnancy or nursing~* And psychological, familial or sociological factors that would preclude study participation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- transurethral resection alone (Type: NO_INTERVENTION): Patients with non-muscle invasive bladder cancer who underwent transurethral resection alone;
- intravesical mitomycin-C (Type: ACTIVE_COMPARATOR): Patients with non-muscle invasive bladder cancer who underwent one intravesical instillation of mitomycin-C immediately after transurethral resection
- electromotive mitomycin-C (Type: EXPERIMENTAL): Patients with non-muscle invasive bladder cancer who underwent single immediate intravesical instillation of electromotive mitomycin-C immediately before transurethral resection

Based on this trial design, predict the completion outcome and termination type (if applicable).